Biosceptre is pleased to announce the grant of a pivotal U.S. patent providing broad protection for CAR-T therapies targeting non-functional P2X7 (nfP2X7). The patent was officially granted by the United States Patent and Trademark Office on 22 October 2024.
This milestone strengthens Biosceptre’s intellectual property position in one of the most important global markets for advanced therapeutics. The patent offers comprehensive coverage for any CAR-T product directed against nfP2X7, a novel cancer target central to Biosceptre’s pipeline of next-generation immunotherapies.
This U.S. grant follows earlier approvals of the same patent in Europe and Australia (2020), Japan (2021), and China (2022), reflecting the global scope and strategic value of the technology.
The patent is part of Biosceptre’s broader IP strategy to ensure robust protection across all major jurisdictions for its innovative products and platforms. Further patent filings are planned as specific product candidates continue to advance through development.
This grant marks a significant step in Biosceptre’s mission to deliver cutting-edge, targeted immunotherapies to patients worldwide.